We have now applied this HISCL system to measure sPD-1, sPD-L1, and sCTLA-4 in pretreatment plasma of patients with advanced NSCLC treated with PD-1/PD-L1 blockade therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.